JPH0466537B2 - - Google Patents
Info
- Publication number
- JPH0466537B2 JPH0466537B2 JP63143375A JP14337588A JPH0466537B2 JP H0466537 B2 JPH0466537 B2 JP H0466537B2 JP 63143375 A JP63143375 A JP 63143375A JP 14337588 A JP14337588 A JP 14337588A JP H0466537 B2 JPH0466537 B2 JP H0466537B2
- Authority
- JP
- Japan
- Prior art keywords
- wheat
- food
- obesity
- wheat flour
- dryness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000209140 Triticum Species 0.000 claims description 25
- 235000021307 Triticum Nutrition 0.000 claims description 25
- 235000013312 flour Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 12
- 230000003579 anti-obesity Effects 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 235000013373 food additive Nutrition 0.000 claims description 9
- 239000002778 food additive Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 235000015099 wheat brans Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000006286 aqueous extract Substances 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000001885 phytohemagglutinin Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000004203 pancreatic function Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102000001746 Pancreatic alpha-Amylases Human genes 0.000 description 2
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- -1 lipase inhibitors Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cereal-Derived Products (AREA)
Description
【発明の詳細な説明】
〈産業上の利用分野〉
本発明は消化酵素阻害物質を含む小麦より最も
適切、廉價な方法によつて得られるそれ自体抗肥
満性食品、抗肥満性食品添加剤、それを混合して
得られる抗肥満性小麦食品、ならびに脂肪の消化
吸収阻害作用の高いペクチンとの混合食品に関す
る。[Detailed Description of the Invention] <Industrial Application Field> The present invention provides an anti-obesity food per se, an anti-obesity food additive, obtained from wheat containing digestive enzyme inhibitors by the most suitable and inexpensive method. The present invention relates to an anti-obesity wheat food obtained by mixing the same, as well as a mixed food with pectin, which has a high effect of inhibiting fat digestion and absorption.
〈従来の技術〉
1940年代、小麦にα−アミラーゼを阻害する蛋
白分画が存在することが報告されて以来、この分
画の分析(例えば主要な3群の阻害物が明らかに
された)、その蛋白質の構造の解析、その応用が
研究されてきた。<Prior art> Since the existence of a protein fraction in wheat that inhibits α-amylase was reported in the 1940s, analysis of this fraction (for example, three major groups of inhibitors were identified), Analysis of the protein structure and its applications have been studied.
応用面については、抗糖尿剤、抗肥満剤の開発
が考えられた。併し、第1の難関は小麦のこの分
画の毒性−例えば下痢−であつた。これはフイト
ヘマグルチニン(Phytohemaeglutinin)の発見、
その解析によつて打開された。こうして、部分的
に純化された小麦分画の抽出法が考案されたが、
所謂スターチ・ブロツカーのヒトに対する抗肥満
剤としての応用は失敗に終つた。そして現在で
は、主力は糖尿病治療剤の開発に向つている。 Regarding applications, development of anti-diabetic agents and anti-obesity agents was considered. However, the first challenge was the toxicity of this fraction of wheat, such as diarrhea. This is due to the discovery of phytohemaeglutinin,
This analysis led to a breakthrough. Thus, a method for extracting a partially purified wheat fraction was devised.
The application of so-called starch Brodsker as an anti-obesity agent to humans ended in failure. Currently, the company's main focus is on the development of antidiabetic agents.
〈発明が解決しようとする問題点〉
上記シユガー・ブロツカーの失敗の原因は今尚
不明であるが、(イ)二炭糖、単糖(グルコース、フ
ルクトースなど)の制限を行なわなかつたこと、
(ロ)抗肥満が単に澱粉の消化吸収阻害のみで達成さ
れる筈のないこと、(ハ)膵α−アミラーゼ分泌のア
ダプテーシヨンの有無などが考えられる。<Problems to be Solved by the Invention> The causes of the Shuger-Brotzker failure described above are still unknown, but (a) they did not restrict dicarbons and monosaccharides (glucose, fructose, etc.);
(b) Anti-obesity cannot be achieved simply by inhibiting the digestion and absorption of starch, and (c) there may be an adaptation of pancreatic α-amylase secretion.
〈問題点を解決するための手段〉
本発明者は小麦に含まれるα−アミラーゼ阻害
物質のみならず、トリプシン阻害物質、リパーゼ
阻害物質、脂肪吸収阻害物質の全体に配慮を及ぼ
し、これら物質の適切、妥当な配合比の研究を行
つてきた。その長い年月の努力の結果、廉価にし
て利用性の高い抗肥満性の小麦食品もしくは食品
添加剤の製造開発に成功した。即ち本発明によれ
ば、小麦粉又は小麦のふすまの水抽出液から、加
熱によりフイトヘマグルチニンを除去した分画か
ら更に低分子量の物質を除いて得られた液状組成
物又はこれを蒸発乾固して得られる粉末、上記小
麦粉源、小麦ふすま源からの液状組成物又は粉末
の混合物、さらにそれにペクチンを添加してなる
組成物からなる、抗肥満性食品、食品添加剤なら
びにこれを添加した各種抗肥満性混合食品が提供
される。<Means for Solving the Problems> The present inventor has given consideration not only to α-amylase inhibitors contained in wheat, but also to trypsin inhibitors, lipase inhibitors, and fat absorption inhibitors, and has determined the appropriateness of these substances. , we have been conducting research on appropriate mixing ratios. As a result of many years of efforts, we have succeeded in producing and developing anti-obesity wheat foods and food additives that are inexpensive and highly usable. That is, according to the present invention, a liquid composition obtained by further removing low molecular weight substances from a fraction obtained by removing phytohemagglutinin by heating from an aqueous extract of wheat flour or wheat bran, or evaporating this to dryness. anti-obesity foods, food additives, and various anti-obesity foods, food additives, and food additives, which are made of powder obtained from wheat bran, liquid compositions or powder mixtures from the flour sources and wheat bran sources, and compositions obtained by adding pectin thereto. Obesity mixed food is provided.
〈実施例〉
以下に本発明小麦食品(添加剤)の製造例、使
用例(効果比較例)などをかかげて本発明を具体
的に説明する。<Example> The present invention will be specifically described below with reference to production examples and usage examples (effect comparison examples) of the wheat food (additive) of the present invention.
実施例1 (小麦粉水抽出物の製法)
小麦粉を重量比で4〜5倍量の水に溶解、低温
(例えば4℃)で4〜5時間撹拌後、低温で1夜
静置。上清をとり80℃、30分間加熱。この液を急
冷後、低温で1夜静置後、上清を適当な方法で乾
固(例えばspray dry法)した。Example 1 (Production method of water extract of wheat flour) Wheat flour was dissolved in 4 to 5 times the amount of water by weight, stirred at a low temperature (for example, 4° C.) for 4 to 5 hours, and then left at a low temperature overnight. Remove the supernatant and heat at 80°C for 30 minutes. After quenching this solution, it was allowed to stand overnight at a low temperature, and the supernatant was dried by an appropriate method (eg, spray dry method).
この粉末は蛋白質重量18%、糖質重量65%、他
は灰分、水からなり、蛋白分割には唾液、α−ア
ミラーゼ、膵液α−アミラーゼ、トリプシンの阻
害物質を含有することが明かにされた。 This powder consists of 18% protein by weight, 65% carbohydrate by weight, and the rest is ash and water, and it was revealed that it contains inhibitors of saliva, α-amylase, pancreatic juice α-amylase, and trypsin for protein resolution. .
但し、味は苦渋にして、吸濕性極めて大で、使
用に堪えないことが判明した。 However, it was found that the taste was bitter and the absorbency was extremely high, making it unsuitable for use.
そこで、膜フイルターを用い、無機物、特にマ
グネシウム、硫酸根を除去し、更に分子量1万以
下の低分子化合物の除去をも行つた。種々の試行
さく誤の後、満足すべき結果に達した。 Therefore, a membrane filter was used to remove inorganic substances, particularly magnesium and sulfate groups, and also to remove low molecular weight compounds with a molecular weight of 10,000 or less. After various trials and errors, a satisfactory result was reached.
実施例2 (小麦ふすまの水抽出法)
小麦ふすまを微細な粒子に粉砕する。粒度は微
細な程よい。これを実施例1の方法にならい、水
抽出し、膜フイルターにより無機分と分子量1万
以下の低分子化合物をを除去した。Example 2 (Wheat bran water extraction method) Wheat bran is ground into fine particles. The particle size is fine. This was extracted with water according to the method of Example 1, and inorganic components and low molecular weight compounds with a molecular weight of 10,000 or less were removed using a membrane filter.
この抽出物は軽度(小麦粉の半分強位)のα−
アミラーゼ阻害作用と強いリパーゼ阻害作用を示
した。 This extract has a mild α-
It showed amylase inhibitory effect and strong lipase inhibitory effect.
実施例3 (小麦粉水抽出物のラツトに対する作
用)
Wistar雄ラツトSPF各5匹、計10匹を使用し
た。1群(対照群)は飼料powder chow(CleaC
−2)、投与群は小麦粉水抽出物10%含有の同飼
料で12日間飼育した。この結果を示すために添付
第1図に体重増加曲線と摂食量を記載した。摂食
量に変化がないにもかかわらず、投与群の体重増
加が著明に抑制されることが明らかである。Example 3 (Effect of water extract of wheat flour on rats) A total of 10 male Wistar rats, 5 each of SPF, were used. Group 1 (control group) was fed powder chow (CleaC
-2), the administration group was fed the same diet containing 10% wheat flour water extract for 12 days. In order to show the results, the weight gain curve and food intake are shown in the attached Figure 1. It is clear that the weight gain of the treated group was significantly suppressed, even though there was no change in the amount of food intake.
血液生化学的所見からは、腎機能、膵機能には
変化なく、肝機能、特にGOTから見て改善の傾
向があつた。 Blood biochemical findings showed that there was no change in renal function or pancreatic function, but there was a tendency for liver function, especially GOT, to improve.
実施例6 (ヒトに対する小麦粉水抽出物の作
用)
皮脂肪量、体重、身長の測定から高度肥満と診
断された成人男子5名に、毎食時小麦粉水抽出物
3g、1ケ月間投与した。体重は7〜2.5Kgの減
少が認められた。Example 6 (Effect of wheat flour aqueous extract on humans) 3 g of wheat flour aqueous extract was administered with each meal for one month to five male adults who were diagnosed as severely obese based on measurements of skin fat content, body weight, and height. A decrease in body weight of 7 to 2.5 kg was observed.
血液生化学的所見は、腎機能、膵機能に変化が
ないこと、血糖値の高いものは低下、肝機能は正
常化されることを示唆した。但し、中性脂肪は増
加の傾向を示した。 Blood biochemical findings suggested that there were no changes in renal or pancreatic function, that high blood sugar levels were reduced, and that liver function was normalized. However, neutral fat showed a tendency to increase.
実施例7 (小麦粉水抽出物(A)と小麦ふすま水抽
出物(B)の投与効果)
Wistar雄ラツトSPF各5匹、計10匹を用いた。
一群5匹は粉末飼料(CleaC−2)で、投与群5
匹はA:B=1:1の混合物を10%含有する粉末
飼料(CleaC−2)で飼育した。飼育期間は15日
であつた。Example 7 (Administration effects of wheat flour water extract (A) and wheat bran water extract (B)) A total of 10 Wistar male rats, 5 each of SPF, were used.
Each group of 5 animals received powdered feed (CleaC-2);
The animals were fed a powdered diet (CleaC-2) containing 10% of a 1:1 mixture of A:B. The breeding period was 15 days.
今回も投与群の体重増加は有意(P<0.01)に
抑制された。血液生化学的所見からは、腎機能、
膵機能の障害は認められなかつた。著明な変化は
中性脂肪の低下、総コレステロールの低下(共に
P<0.05で有意)、GTPのの低下傾向とGOTの明
らかな低下であつた。 This time as well, weight gain in the administered group was significantly suppressed (P<0.01). Blood biochemical findings indicate renal function,
No impairment of pancreatic function was observed. Remarkable changes were a decrease in triglycerides, a decrease in total cholesterol (both significant at P<0.05), a tendency toward a decrease in GTP, and a clear decrease in GOT.
実施例8 (小麦粉水抽出物(A)とペクチン(B)の投
与効果)
A:B=1:1の混合比の粉末を10%の濃度で
含有する飼料を用い、実施例7と同様の実験を行
つた。Example 8 (Effect of administration of wheat flour water extract (A) and pectin (B)) The same procedure as in Example 7 was carried out using feed containing powder at a mixing ratio of A:B=1:1 at a concentration of 10%. I conducted an experiment.
実験成績は実施例7ほど著明ではなかつたが、
同様の傾向を示した。 Although the experimental results were not as remarkable as in Example 7,
showed similar trends.
実施例9 (ヒトに対する小麦粉水抽出液(A′)
と小麦ふすま水抽出液(B′)の投与効果)
濃縮A′と濃縮B′とを各2.5ml、計5mlを毎食時
服用、1ケ月継続の投与効果を検討した。成人男
子(3名)、女子(3名)、中等度肥満のものを用
いた。体重は男子平均5Kg、女子平均5.6Kg減少
した。Example 9 (Wheat flour water extract for humans (A')
2.5 ml each of Concentrated A' and Concentrated B', a total of 5 ml, was taken with every meal, and the effects of administration were examined for one month. Adult males (3 subjects) and females (3 subjects) with moderate obesity were used. Weight decreased by an average of 5 kg for boys and 5.6 kg for women.
血液生化学的所見からは、腎、膵の機能障害は
認められなかつた。肝機能の改善、中性脂肪の明
らかな(P<0.05で有意)低下が見られた。総コ
レステロールも減下の傾向を示した。血糖値は一
般に低下の傾向を示した。 Blood biochemical findings showed no renal or pancreatic dysfunction. An improvement in liver function and a clear (significant at P<0.05) decrease in triglyceride levels were observed. Total cholesterol also showed a decreasing trend. Blood sugar levels generally showed a decreasing trend.
実施例10 多量のA′+B′混合液の効果
A′、B′各5ml、計10mlの毎食時服用効果を高
度肥満成人女子5名を用いて、検討した。Example 10 Effect of a large amount of A'+B' mixed solution The effect of taking 5 ml each of A' and B' (total 10 ml) with each meal was investigated using five severely obese adult females.
1ケ月服用継続で体重は平均6.5Kg減量した。
血液生化学的所見は実施例9と同様であつた。 After continuing to take the drug for one month, I lost an average of 6.5 kg.
Blood biochemical findings were the same as in Example 9.
第1図は小麦粉水抽出物配合飼料によるラツト
の飼育試験結果を示すグラフである。
FIG. 1 is a graph showing the results of a rat rearing test using a wheat flour water extract-containing feed.
Claims (1)
マグルチニンを除去した分画より、分子量1万以
下の物質を除いて得られた液状組成物、又は更に
これを蒸発乾固して得られた粉末からなる抗肥満
性小麦食品及び食品添加剤。 2 上記小麦粉の水抽出物の代わりに小麦のふす
まの水抽出液を使用した請求項1に記載の抗肥満
性小麦食品及び食品添加剤。 3 請求項1項と2項とに記載の水抽出物とを
1:10から10:1の重量比で混合して得られた液
状組成物又は更にこれを蒸発乾固して得られた粉
末からなる抗肥満性小麦食品及び食品添加剤。 4 請求項1項に記載の液状組成物とペクチンと
を1:10〜10:1の重量比で混和して得られる液
状物又は更にこれを蒸発乾固して得られた粉末か
らなる抗肥満性小麦食品及び食品添加剤。[Claims] 1. A liquid composition obtained by removing substances with a molecular weight of 10,000 or less from a fraction obtained by removing phytohemagglutinin from a water extract of wheat flour by heating, or further evaporating this to dryness. An anti-obesity wheat food and food additive consisting of powder obtained by 2. The anti-obesity wheat food and food additive according to claim 1, wherein an aqueous extract of wheat bran is used instead of the aqueous extract of wheat flour. 3. A liquid composition obtained by mixing the water extracts according to claims 1 and 2 at a weight ratio of 1:10 to 10:1, or a powder obtained by further evaporating this to dryness. An anti-obesity wheat food and food additive consisting of: 4. An anti-obesity product comprising a liquid obtained by mixing the liquid composition according to claim 1 and pectin at a weight ratio of 1:10 to 10:1, or a powder obtained by further evaporating this to dryness. wheat food and food additives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63143375A JPH01312975A (en) | 1988-06-10 | 1988-06-10 | Anti-obesity food of wheat origin and food additive therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63143375A JPH01312975A (en) | 1988-06-10 | 1988-06-10 | Anti-obesity food of wheat origin and food additive therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01312975A JPH01312975A (en) | 1989-12-18 |
| JPH0466537B2 true JPH0466537B2 (en) | 1992-10-23 |
Family
ID=15337325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63143375A Granted JPH01312975A (en) | 1988-06-10 | 1988-06-10 | Anti-obesity food of wheat origin and food additive therefor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01312975A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001299242A (en) * | 2000-04-28 | 2001-10-30 | Kanebo Ltd | Gelling agent-containing food and method for producing the same |
-
1988
- 1988-06-10 JP JP63143375A patent/JPH01312975A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH01312975A (en) | 1989-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU628514B2 (en) | Inhibitive agent against activity of alpha-amylase | |
| Tamir et al. | Carob tannins—growth depression and levels of insoluble nitrogen in the digestive tract of rats | |
| CN104222999B (en) | Composition, preparation and application of a novel low-sodium salt | |
| JP2002154977A (en) | Food composition | |
| FR2527446A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF PAPAINE AND CITRIC ACID, WHICH CAN BE TAKEN IN A FOOD OR BEVERAGE | |
| JP4002654B2 (en) | Blood lipid improving agent, cyclic AMP phosphodiesterase inhibitor, obesity preventive / eliminating agent, food and beverage, and skin external preparation | |
| JP4499209B2 (en) | Obesity prevention and improvement agent | |
| JP2004000171A (en) | Functional food product containing maca | |
| JP2002524419A (en) | Compositions for improving mental performance in mammals | |
| JPH0466537B2 (en) | ||
| JP3496625B2 (en) | Health food composition | |
| JPH1149690A (en) | Composition for stimulating lipolysis | |
| JP4783882B2 (en) | Novel α-amylase inhibitory active substance, production method thereof and use thereof | |
| JPH0716382B2 (en) | Method for producing seaweed minerals | |
| KR20050120302A (en) | Amylase inhibitor for anti-obesity and use | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| JP3980952B2 (en) | Enteric fat absorption inhibitor containing plant extract and food containing the same | |
| JPH092966A (en) | Amylase inhibitor obtained from button pie and diet food containing the same | |
| JPH0833464A (en) | Solid food for lean body | |
| JP3183754B2 (en) | Arteriosclerosis inhibitor and composition containing the same | |
| JP4892833B2 (en) | Fat absorption inhibitor | |
| JPH10306032A (en) | Energy enhancer | |
| KR100786363B1 (en) | Natural complex concentrates that have improved cholesterol metabolism and anti-obesity at the same time and manufacturing method | |
| JP2006241039A (en) | Urease inhibitor | |
| EP0398525A1 (en) | Compositions, containing inositol phosphate, preparation and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081023 Year of fee payment: 16 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081023 Year of fee payment: 16 |